Cargando…
Kawasaki Disease-Management Strategies Given Symptoms Overlap to COVID-19: A Review
Kawasaki disease is an acute, self-limiting vasculitis in children. Early treatment is necessary to prevent cardiovascular complications. The acute phase of Kawasaki disease may present with hemodynamic instability. An association between viral respiratory infections and Kawasaki disease has been re...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Journal of the Nepal Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369595/ https://www.ncbi.nlm.nih.gov/pubmed/34508537 http://dx.doi.org/10.31729/jnma.5698 |
_version_ | 1783739325847961600 |
---|---|
author | Wang, Linna Zhang, Sheng Ma, Ji Ni, Jing Wang, Juyan Li, Xiaohong Mu, Zhilong Han, Wei He, Gaitao Ma, Lei Shah, Jenifei Shah, Jay Jiao, Fuyong |
author_facet | Wang, Linna Zhang, Sheng Ma, Ji Ni, Jing Wang, Juyan Li, Xiaohong Mu, Zhilong Han, Wei He, Gaitao Ma, Lei Shah, Jenifei Shah, Jay Jiao, Fuyong |
author_sort | Wang, Linna |
collection | PubMed |
description | Kawasaki disease is an acute, self-limiting vasculitis in children. Early treatment is necessary to prevent cardiovascular complications. The acute phase of Kawasaki disease may present with hemodynamic instability. An association between viral respiratory infections and Kawasaki disease has been reported. Studies have shown that Kawasaki and Kawasaki-like disease may be associated with and have symptoms overlapping COVID-19. Children with COVID-19 may present as Kawasaki-like disease with pediatric inflammatory multisystem syndrome, or macrophage activation syndrome. Clinicians need to be aware of the early diagnosis and management of Kawasaki disease to prevent the development of coronary artery aneurysms. The symptoms overlap of multisystem inflammatory disease seen in COVID-19 adds to the difficulties in timely diagnosis and treatment. Children with Kawasaki disease require regular follow-up plans for coronary artery aneurysms. This adds to the difficulties during the changed environment of COVID-19 for control and prevention. Missed diagnosis and early treatment of Kawasaki disease with immunoglobulin and aspirin results in the development of coronary artery aneurysm in up to 25% of cases, with grave consequences. Here, we briefly review the management of typical and atypical Kawasaki disease which has symptoms overlapping with the multisystem inflammatory disease as seen in COVID-19. |
format | Online Article Text |
id | pubmed-8369595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Journal of the Nepal Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-83695952021-08-26 Kawasaki Disease-Management Strategies Given Symptoms Overlap to COVID-19: A Review Wang, Linna Zhang, Sheng Ma, Ji Ni, Jing Wang, Juyan Li, Xiaohong Mu, Zhilong Han, Wei He, Gaitao Ma, Lei Shah, Jenifei Shah, Jay Jiao, Fuyong JNMA J Nepal Med Assoc Review Article Kawasaki disease is an acute, self-limiting vasculitis in children. Early treatment is necessary to prevent cardiovascular complications. The acute phase of Kawasaki disease may present with hemodynamic instability. An association between viral respiratory infections and Kawasaki disease has been reported. Studies have shown that Kawasaki and Kawasaki-like disease may be associated with and have symptoms overlapping COVID-19. Children with COVID-19 may present as Kawasaki-like disease with pediatric inflammatory multisystem syndrome, or macrophage activation syndrome. Clinicians need to be aware of the early diagnosis and management of Kawasaki disease to prevent the development of coronary artery aneurysms. The symptoms overlap of multisystem inflammatory disease seen in COVID-19 adds to the difficulties in timely diagnosis and treatment. Children with Kawasaki disease require regular follow-up plans for coronary artery aneurysms. This adds to the difficulties during the changed environment of COVID-19 for control and prevention. Missed diagnosis and early treatment of Kawasaki disease with immunoglobulin and aspirin results in the development of coronary artery aneurysm in up to 25% of cases, with grave consequences. Here, we briefly review the management of typical and atypical Kawasaki disease which has symptoms overlapping with the multisystem inflammatory disease as seen in COVID-19. Journal of the Nepal Medical Association 2021-04 2021-04-30 /pmc/articles/PMC8369595/ /pubmed/34508537 http://dx.doi.org/10.31729/jnma.5698 Text en © The Author(s) 2018. https://creativecommons.org/licenses/by/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Wang, Linna Zhang, Sheng Ma, Ji Ni, Jing Wang, Juyan Li, Xiaohong Mu, Zhilong Han, Wei He, Gaitao Ma, Lei Shah, Jenifei Shah, Jay Jiao, Fuyong Kawasaki Disease-Management Strategies Given Symptoms Overlap to COVID-19: A Review |
title | Kawasaki Disease-Management Strategies Given Symptoms Overlap to COVID-19: A Review |
title_full | Kawasaki Disease-Management Strategies Given Symptoms Overlap to COVID-19: A Review |
title_fullStr | Kawasaki Disease-Management Strategies Given Symptoms Overlap to COVID-19: A Review |
title_full_unstemmed | Kawasaki Disease-Management Strategies Given Symptoms Overlap to COVID-19: A Review |
title_short | Kawasaki Disease-Management Strategies Given Symptoms Overlap to COVID-19: A Review |
title_sort | kawasaki disease-management strategies given symptoms overlap to covid-19: a review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369595/ https://www.ncbi.nlm.nih.gov/pubmed/34508537 http://dx.doi.org/10.31729/jnma.5698 |
work_keys_str_mv | AT wanglinna kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT zhangsheng kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT maji kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT nijing kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT wangjuyan kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT lixiaohong kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT muzhilong kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT hanwei kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT hegaitao kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT malei kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT shahjenifei kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT shahjay kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview AT jiaofuyong kawasakidiseasemanagementstrategiesgivensymptomsoverlaptocovid19areview |